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The Regulation of Fatty Acid Synthase by STAT5A
Jessica C. Hogan and Jacqueline M. Stephens

Growth hormone (GH) diminishes adipose tissue mass
in vivo and decreases expression and activity of fatty
acid synthase (FAS) in adipocytes. GH and prolactin
(PRL) are potent activators of STAT5 and exert adipogenic and antiadipogenic effects in adipocytes. In this
study, we demonstrate that GH and PRL decrease the
mRNA and protein levels of FAS in 3T3-L1 adipocytes.
We present evidence that indicates that FAS is repressed at the level of transcription. In addition, PRL
responsiveness was shown to exist between ⴚ1,594 and
ⴚ700 of the rat FAS promoter. Moreover, responsiveness to PRL was abolished with mutation of a site at
position ⴚ908 to ⴚ893, which we have shown to bind
STAT5A in a PRL-dependent manner. Taken together,
these data strongly suggest that PRL directly represses
expression of FAS in adipocytes through STAT5A binding to the ⴚ908 to ⴚ893 site. Furthermore, our results
indicate that STAT5A has an antilipogenic function in
adipocytes and may contribute to the regulation of
energy balance. Diabetes 54:1968 –1975, 2005

S

TAT5 proteins were first identified as mammary
gland factor, a protein from mouse mammary
glands that is bound to the ␤-casein promoter (1).
It was subsequently determined that mammary
gland factor was two closely related proteins, STAT5A and
STAT5B (2), that are expressed in all tissues (3). Transgenic deletion studies in mice indicate that a major function of STAT5 proteins is the regulation of mammary
tissue development (4), but multiple lines of evidence
suggest a role for STAT5 proteins in the modulation of
adipocyte function. During differentiation of 3T3-L1 adipocytes, expression levels of STAT5A and 5B were highly
induced (5). Furthermore, growth hormone (GH)-dependent adipogenesis was attenuated by STAT5 antisense
oligonucleotides (6), and constitutively active STAT5 can
replace the requirement for GH in the adipogenesis of
murine 3T3-F442A cells (7). Moreover, ectopic expression
of STAT5A conferred adipogenesis in two different nonprecursor cell lines (8). Transgenic deletion of STAT5A,
STAT5B, or both STAT5 genes in mice resulted in signifi-
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cantly reduced fat-pad sizes compared with wild-type mice
(4). Yet, in primary cultures of adipose tissue from these
animals, GH did not stimulate lipolysis as it does in
adipocytes from wild-type mice (9). Also, chronic administration of GH in pigs decreases adipose tissue growth
through the attenuation of lipogenesis (10,11) and reduces
adipocyte conversion in rat primary adipocytes (12). More
recent studies suggest that some of the antiadipogenic
effects of GH may be mediated by STAT5A. In rat primary
preadipocytes, GH-induced STAT5 inhibits aP2 expression
(13). In summary, STAT5 proteins appear to have both
adipogenic as well as antiadipogenic effects in adipose
tissue of various species, which may depend on the
developmental stage of the tissue.
PRL is a peptide hormone primarily known for its role in
mammary gland development during lactation, but it has
been shown to have pleiotropic effects in a variety of
tissues (14). PRL activates multiple signal transduction
pathways, including mitogen-activated protein kinase (15)
and phosphatidylinositol-3 kinase (16); however, the JAK/
STAT pathway is the predominant signaling cascade activated by PRL, resulting in the nuclear translocation of
STAT5 proteins (3).
The regulation of mammary tissue by PRL is well
characterized, but there is also evidence that PRL modulates adipose tissue. PRL-R is expressed in both mouse
(17) and human (18) adipose tissue and is induced during
adipogenesis of bone marrow stromal cells (19). Furthermore, ectopic expression of the PRL-R in murine NIH-3T3
cells resulted in efficient adipocyte conversion and activation of the aP2 promoter in a PRL-dependent manner (20).
Taken together, these observations strongly suggest a role
for PRL in the modulation of adipocyte function. Furthermore, the occurrence of obesity has been correlated with
hyperprolactinomas in humans (21). In opposition to these
adipogenic effects, PRL has been shown to induce lipolysis
in rabbits (22) and mouse adipose tissue explants (23). In
addition, studies have shown that PRL reduces lipoprotein
lipase (LPL) activity in cultured human adipocytes (18)
and the activity of LPL and fatty acid synthase (FAS) in
adipose tissue of lactating mice (24). Thus, PRL exerts
adipogenic and antilipogenic effects on adipose tissue in a
variety of species.
FAS is the key enzyme in de novo lipogenesis, catalyzing
the reactions for the synthesis of long-chain fatty acids
(25). The importance of FAS in adipocyte function is
underscored by the inhibition of adipogenesis of 3T3-L1
cells by C75, an allosteric inhibitor of FAS (26). FAS is
regulated primarily at the level of transcription and is
sensitive to nutritional and hormonal regulation (25).
Previous studies have demonstrated that GH, a cytokine
that activates STAT5 in adipocytes (27), abrogates the
induction of FAS expression by insulin and downregulates
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basal expression of FAS in 3T3-F442A cells (28). Although
insulin-regulated regions of the FAS promoter have been
extensively studied, there has not been a conclusive study
to characterize a GH-responsive region or to determine the
potential role of STATs in the modulation of FAS expression. Since GH and PRL are potent activators of STAT5
(27,20), we hypothesized that STAT5 directly regulates the
expression of FAS. In this study, we have demonstrated
that GH and PRL treatment of 3T3-L1 adipocytes resulted
in decreased FAS mRNA and protein. In addition, we have
identified a region within the FAS promoter that is responsive to PRL. This region contains a nonconsensus STAT5
binding site that, when mutated, results in a loss of
sensitivity to PRL. Our results clearly demonstrate that
STAT5A binds to this nonconsensus sequence and strongly
suggest that FAS is a direct target for regulation by STAT5.
These data suggest a novel means for regulation of FAS
expression in adipocytes and reveal a mechanism by
which STAT5 proteins and PRL exert antiadipogenic effects.
RESEARCH DESIGN AND METHODS
Dulbecco’s modified Eagle medium (DMEM) and leukemia inhibitory factor
(LIF) were purchased from Invitrogen. Fetal bovine serum was purchased
from Atlanta Biologicals, and calf serum was purchased from Biosource.
Polyclonal phospho-specific STAT5 (Y694) antibody and FAS antibody were
purchased from BD Transduction Laboratories. STAT1 antibody was purchased from Upstate Biotechnology. Porcine growth hormone, ovine PRL
(both prepared from pituitaries), and cycloheximide were purchased from
Sigma. STAT3 and STAT5A antibodies were purchased from Santa Cruz.
[␣-32P] dCTP was purchased from Perkin-Elmer and Amersham Biosciences.
Deoxynucleotide thymine triphosphate, dATP, and dGTP were purchased
from Amersham Biosciences. Oligonucleotides were purchased from Integrated DNA Technologies. DNase polymerase I large (Klenow) fragment was
purchased from Promega.
Cell culture. Murine 3T3-L1 preadipocytes were plated and grown to 2 days
postconfluence in DMEM containing 10% bovine serum. Medium was changed
every 48 h. Cells were induced to differentiate by changing the medium to
DMEM containing 10% fetal bovine serum, 0.5 mmol/l 3-isobutyl-methylxanthine, 1 mol/l dexamethasone, and 1.7 mol/l insulin. After 48 h, this medium
was replaced with DMEM supplemented with 10% fetal bovine serum, and the
cells were maintained in this medium until used for experimentation.
Preparation of whole-cell extracts. Cell monolayers were rinsed with PBS
and then harvested in a nondenaturing buffer containing 10 mmol/l Tris (pH
7.4), 150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X-100, 0.5%
Nonidet P-40, 1 mol/l phenylmethylsulfonyl fluoride, 1 mol/l pepstatin, 50
trypsin inhibitory mU aprotinin, 10 mol/l leupeptin, and 2 mmol/l sodium
vanadate. Samples were extracted for 30 min on ice and centrifuged at 15,000
rpm at 4°C for 15 min. Supernatants containing whole-cell extracts were
analyzed for protein content by bicinchoninic acid analysis (Pierce) according
to the manufacturer’s instructions.
RNA analysis. Total RNA was isolated from cell monolayers with Trizol
(Invitrogen), according to manufacturer’s instructions with minor modifications. For Northern blot analysis, 15 g total RNA was denatured in formamide and electrophoresed through a formaldehyde/agarose gel. The RNA
was transferred to Zeta Probe-GT (Bio-Rad) in a buffer containing 75 mmol/l
sodium citrate tribasic, 10 mmol/l NaOH, and 750 mmol/l NaCl. The blots were
cross-linked, hybridized, and washed as previously described (29). Probes
were labeled by random priming using Klenow fragment and [␣-32P] dCTP.
Constructs. The rat FAS promoter ⫺250 to ⫹65/luciferase construct was
generously provided by Dr. Steve Clarke. The rat FAS promoter ⫺1,594 to
⫹65/luciferase and ⫺700 to ⫹65/luciferase constructs were generously provided by Dr. Peter Tontonoz. The FAS ⫺1,594 to ⫹65/luciferase construct was
mutated at positions ⫺901 and ⫺902 within the STAT5A binding site using the
QuikChange Site Directed Mutagenesis Kit, according to manufacturer’s
instructions (Stratagene). The following oligonucleotide and corresponding
antisense oligonucleotide were used to alter the STAT binding site with the
altered bases underlined: GGG AGG GTG AGG GTC AAG GAA ACC AGC AAC
TCA GG. Sequence analysis was performed to confirm the presence of the
mutated bases using Big Dye Terminator Extension Reaction (ABI Prism). The
DIABETES, VOL. 54, JULY 2005

minimum promoter thymidine kinase (TK) renilla vector was purchased from
Promega.
Transfection and luciferase assay. 3T3-L1 preadipocytes were transiently
cotransfected with the various FAS promoter constructs and the TK/renilla
vector to control for transfection efficiency, as previously described (30),
using Polyfect (Qiagen) according to manufacturer’s instructions. Cell lysates
were analyzed for firefly and renilla luciferase activity using the Dual
Luciferase Reporter Assay System (Promega). Relative light units were
determined by dividing firefly luciferase activity by renilla luciferase activity.
Results are given as ⫾SD.
Preparation of nuclear and cytosolic extracts. Cell monolayers were
rinsed with PBS and then harvested in a nuclear homogenization buffer
containing 20 mmol/l Tris (pH 7.4), 10 mmol/l NaCl, 3 mmol/l MgCl2, 1 mol/l
dithiothreitol, 1 mol/l phenylmethylsulfonyl fluoride, 1 mol/l pepstatin, 50
trypsin inhibitory mU aprotinin, 10 mol/l leupeptin, and 2 mmol/l sodium
vanadate. Igepal CA-630 (Nonidet P-40) was added to a final concentration of
0.15%, and cells were homogenized with 16 strokes in a Dounce homogenizer.
The homogenates were centrifuged at 1,500 rpm for 5 min. Supernatants were
saved as cytosolic extract, and the nuclear pellets were resuspended in
one-half volume of nuclear homogenization buffer and were centrifuged as
before. The pellet of intact nuclei was resuspended again in one-half of the
original volume of nuclear homogenization buffer and centrifuged again. The
majority of the pellet (intact nuclei) was resuspended in an extraction buffer
containing 20 mmol/l HEPES (pH 7.9), 420 mmol/l NaCl, 1.5 mmol/l MgCl2, 0.2
mmol/l EDTA, 1 mol/l dithiothreitol, 1 mol/l phenylmethylsulfonyl fluoride,
1 mol/l pepstatin, 50 trypsin inhibitory mU aprotinin, 10 mol/l leupeptin, 2
mmol/l sodium vanadate, and 25% glycerol. Nuclei were extracted for 30 min
on ice. The samples were subjected to centrifugation at 10,000 rpm at 4°C for
10 min. Supernatants containing nuclear extracts were analyzed for protein
content, using a bicinchoninic acid protein assay kit (Pierce).
Gel electrophoresis and immunoblotting. Proteins were separated in 6%
polyacrylamide (National Diagnostics) gels containing SDS according to
Laemmli (31) and transferred to nitrocellulose (Bio-Rad) in 25 mmol/l Tris, 192
mmol/l glycine, and 20% methanol. Following transfer, the membrane was
blocked in 4% milk overnight at 4°C. Results were visualized with horseradish
peroxidase– conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) and enhanced chemiluminescence (Pierce).
Electrophoretic mobility shift analysis. Double-stranded oligonucleotides
were end labeled with [␣-32P] dCTP using Klenow. Binding reactions were
performed with nuclear extracts, according to Ritzenthaler et al. (32).
Protein-DNA complexes were resolved and visualized, as previously described
(30). For supershift analysis, nuclear extracts were preincubated with 4 g
antibody for 1 h at room temperature.

RESULTS

GH is known to reduce adipose tissue in vivo (11) and
decrease the expression of FAS in adipocytes (10). GH is
also a potent activator of STAT5 in adipocytes (27). Hence,
we hypothesized that STAT5 proteins directly modulate
FAS expression. Therefore, we examined the regulation of
FAS by two STAT5 activators, GH and PRL. As shown in
Fig. 1A, we observed that both GH and PRL resulted in a
decrease in FAS mRNA in fully differentiated 3T3-L1
adipocytes. GH decreased FAS mRNA by 12 h of treatment, and PRL treatment resulted in decreased expression
within 6 h. In an independent experiment, we observed
that both GH and PRL also resulted in a decrease in
expression of FAS protein levels (Fig. 1B). To demonstrate
the specificity of this effect, fully differentiated 3T3-L1
adipocytes were treated with PRL for 8 h with the various
doses indicated in Fig. 1C. There was a notable decrease in
FAS protein level with 8.8 nmol/l PRL treatment, and the
decrease of FAS protein levels by PRL treatment was dose
dependent. An acute treatment of 1.3 mol/l PRL was
included as a positive control for STAT5 phosphorylation.
The level of STAT5A expression was unchanged by GH or
PRL (Fig. 1B and C) and is shown to indicate even loading
of protein samples.
Clearly, the analysis of mRNA and whole-cell extracts
demonstrated that activators of STAT5 decreased expres1969
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FIG. 1. Activators of STAT5 decrease expression of FAS in
3T3-L1 adipocytes. A: Total RNA was isolated from 3T3-L1
adipocytes following treatment with GH (11.3 nmol/l) or PRL
(1.4 mol/l) for the times indicated. Untreated cells (CTL)
were harvested at the start and end of the time course. Fifteen
micrograms of total RNA was electrophoresed, transferred to
nylon, and subjected to Northern blot analysis with radiolabeled probe for FAS. Ethidium bromide staining of 28S and 18S
RNA is included as a loading control. This is a representative
experiment independently performed two times. B: Mature
3T3-L1 adipocytes were stimulated with GH (11.3 nmol/l) or
PRL (1.4 mol/l) for the times indicated. One hundred micrograms of protein from whole-cell extracts were loaded into the
gel for each sample. The samples were subjected to SDS-PAGE
and were then transferred to nitrocellulose for immunoblot
analysis. This is a representative experiment independently
performed two times. C: Mature 3T3-L1 adipocytes were stimulated with PRL with the doses indicated for 8 h. The (ⴙ)
indicates a sample isolated from fully differentiated 3T3-L1
adipocytes that were treated for 15 min with 1.4 mol/l PRL.
Western analysis was performed as described above. This is a
representative experiment independently performed two
times.

sion of FAS protein and mRNA. Yet, it was unclear if the
effects of GH and PRL were mediated by affecting FAS
transcription and/or protein turnover. To assess whether
the effects of PRL on FAS expression could be attributed
to changes in the turnover of FAS protein, we examined
the loss of FAS in the presence of cycloheximide (5
mol/l) or ethanol, a vehicle control. Whole-cell extracts
were collected at various times and used for Western blot
analysis. As shown in Fig. 2, either cycloheximide or PRL
treatment caused a decrease in FAS protein. In the presence of cycloheximide, a loss of FAS was observed at 8 h,
regardless of the presence of PRL. PRL treatment alone
decreased the level of FAS within 12 h of treatment. These
results indicate that PRL does not affect the turnover of
FAS protein in 3T3-L1 adipocytes and suggest that PRL
may exert its effects on FAS at the level of transcription.
Our data indicate that PRL directly regulates the expression of FAS. Recent studies by Yin, Clarke, and Etherton
(28) have shown that GH abrogates the induction of FAS
by insulin and suggested that the ⫺112 to ⫹65 region of
the rat FAS promoter was sensitive to the regulation by
GH. Therefore, we hypothesized that a STAT5 recognition
element may be present in this region. To address this
question, 3T3-L1 preadipocytes were transiently trans-

FIG. 2. PRL does not affect turnover of FAS protein. Fully differentiated 3T3-L1 adipocytes were treated with cycloheximide (CHX; 5
mol/l) and PRL (1.4 mol/l) for the times indicated. One hundred
micrograms of protein from whole-cell extracts were loaded into the
gel for each sample. The samples were subjected to SDS-PAGE and
were then transferred to nitrocellulose for immunoblot analysis. This
is a representative experiment independently performed two times.
1970

fected with a luciferase construct containing the FAS
promoter fragment of ⫺250 to ⫹65. After 48 h, cells were
stimulated with PRL for the times indicated in Fig. 3A and
were then analyzed for luciferase activity as described in
RESEARCH DESIGN AND METHODS. We observed that PRL treatment had no significant effects on the relative luciferase
activity (Fig. 3A), clearly demonstrating that the ⫺250 to
⫹65 region of the FAS promoter is not sensitive to PRL.
Therefore, we examined the PRL responsiveness of two
additional rat FAS promoter/luciferase constructs that
incorporated larger regions, ⫺1,594 to ⫹65 and ⫺700 to
⫹65, of the promoter. Transfection of these constructs
into 3T3-L1 cells revealed a PRL-responsive region present
between ⫺1,594 and ⫺700 of the rat FAS promoter. As
shown in Fig. 3B, treatment with PRL resulted in a 64%
decrease in luciferase activity of the rat FAS promoter
(⫺1,594 to ⫹65)/luciferase construct. Although the basal
level of luciferase activity for the rat FAS promoter (⫺700
to ⫹65)/luciferase construct was similar to that of the
⫺1,594 to ⫹65 construct, PRL had no effect on the level of
luciferase activity (Fig. 3B). These data demonstrate that a
PRL-sensitive region exists between ⫺1,594 and ⫺700 of
the FAS promoter and support our hypothesis that FAS is
transcriptionally regulated by STAT5 activators.
Since PRL is a potent activator of STAT5, we hypothesized that the ⫺1,594 to ⫺700 region of the FAS promoter
may contain a STAT5 binding site that conferred PRL
responsiveness. Therefore, we examined the rat FAS promoter (GenBank X62889) for the presence of STAT consensus sites (TTCNNNGAA). An examination of the FAS
promoter did not result in the identification of any sequences that precisely matched the STAT consensus site.
However, as shown in Table 1, we identified four regions
that were similar to the consensus sequence. To evaluate
these potential STAT5 binding sites, we performed a series
of electromobility shift assays (EMSA). For these experiDIABETES, VOL. 54, JULY 2005
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FIG. 3. A PRL-responsive region resides between ⴚ1,594 and ⴚ700 of
the rat FAS promoter. A: Proliferating 3T3-L1 cells were transiently
transfected with the rat FAS promoter (ⴚ250 to ⴙ65)/luciferase
construct and the TK/renilla vector to control for transfection efficiency. After 48 h of transfection, cells were stimulated with PRL (2.8
mol/l) for the times indicated. Relative light units (RLU) were
calculated by dividing firefly luciferase activity by renilla luciferase
activity. Results are shown as ⴞSD. B: 3T3-L1 preadipocytes were
transiently transfected with the (ⴚ1,594 to ⴙ65) or (ⴚ700 to ⴙ65) rat
FAS promoter/luciferase constructs. RLU was determined as described
above. For each experiment, three plates of cells were used for each
particular condition. In addition, each experiment was performed on
three independent batches of cells with similar results. Hence, each
condition has n ⴝ 9.

ments, nuclear and cytosolic extracts were prepared from
3T3-L1 adipocytes acutely treated with PRL for 15 min. As
shown in Fig. 4A, PRL did not induce the binding of
nuclear protein complexes to the ⫺951 to ⫺933, ⫺1,226 to
⫺1,214, or ⫺4,639 to ⫺4,623 regions of the FAS promoter.
The induction of binding by a PRL-activated protein complex to the rat ␤-casein STAT5 binding site (1) is included
as a positive control. However, we did observe PRLdependent binding by a nuclear protein complex to the
⫺908 to ⫺893 region of the FAS promoter (Fig. 4B). To
determine the specificity of binding, an EMSA was performed using a mutant version of the ⫺908 to ⫺893
oligonucleotide, in which two nucleotides were changed
(Table 1). As shown in Fig. 4B, there was no detectable
binding to the mutant form of the binding site following
PRL stimulation. In addition, binding of the PRL-activated

FIG. 4. PRL stimulates binding of nuclear proteins to the ⴚ908 to ⴚ893
site in the rat FAS promoter. A: Nuclear extracts were prepared from
differentiated 3T3-L1 adipocytes that were untreated or treated with
PRL (1.4 mol/l) for 15 min. For each sample, 10 g protein were
incubated with 50,000 cpm/ml of the indicated 32P-labeled probe of the
FAS promoter. The protein-DNA complexes were resolved by EMSA.
Binding to the rat ␤-casein (ⴚ101 to ⴚ87) site is included as a positive
control. This is a representative experiment independently performed
two times. B: Binding to the ⴚ908 to ⴚ893 and the mutant oligonucleotides by PRL-induced protein complexes was analyzed as described
above. C: Successive cold competition was performed with 75 nmol/l to
15 mol/l of the unlabeled ⴚ908 to ⴚ893 oligonucleotide. EMSA was
performed as described above. D: Nuclear extracts were preincubated
with an excess of the indicated unlabeled oligonucleotides (15 mol/l).
EMSA was performed as described above.

protein complex was successively competed with increasing concentrations of the unlabeled ⫺908 to ⫺893 oligonucleotide (Fig. 4C). Further evidence of specificity is
shown in Fig. 4D, in which an excess of the ⫺908 to ⫺893

TABLE 1
Potential STAT5 binding sites in the FAS promoter
Gene
Consensus GAS/SIE
FAS
FAS
FAS
FAS
FAS
␤-Casein
DIABETES, VOL. 54, JULY 2005

Position

Sequence

PRL responsive

⫺908 to ⫺893
mutant ⫺908
⫺951 to ⫺931
⫺1,226 to ⫺1,214
⫺4,639 to ⫺4,621
⫺100 to ⫺87

TTC NNN GAA
GGG TCC CGG AAA CCA G
GGG TCA AGG AAA CCA G
C CCT TTC AAA AGA
C TCC TTC CAC AGA GAG
A ACT TTT TGA AAC
G GTT TTC TTG GAA TT

Yes
No
No
No
No
Yes
1971
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FIG. 5. PRL induces STAT5A binding to the ⴚ908 to ⴚ893 site in the rat
FAS promoter. Nuclear extracts were prepared from 3T3-L1 adipocytes
treated with PRL (1.4 mol/l) or LIF (0.5 nmol/l) for 15 min. For each
sample, 10 g protein were preincubated with 4 g of the indicated
antibody and then incubated with 50,000 cpm/ml of the indicated
32
P-labeled probe of the ⴚ908 to ⴚ893 site in the FAS promoter. The
protein-DNA complexes were resolved by EMSA. This is a representative experiment independently performed two times.

oligonucleotide competed away binding induced by PRL
treatment (lane 4), whereas the mutant form of the
oligonucleotide did not (lane 5). Although we did not
detect binding to the ⫺951 to ⫺933 site, an excess of this
oligonucleotide moderately diminished binding to the radiolabeled ⫺908 to ⫺893 probe (lane 6). Yet, there was no
appreciable competition of binding by the ⫺1,226 to
⫺1,214 oligonucleotide (lane 7). As anticipated, binding
was competed away with the STAT5 binding site of the rat
␤-casein promoter. Interestingly, a STAT3 binding site,
⫺168 to ⫺148 from the rat ␣2-macroglobulin promoter
(33), also resulted in binding competition. However, binding was not competed with a STAT1 binding site that is
present at ⫺221 to ⫺207 of the peroxisome proliferator–
activated receptor ␥2 promoter (34).
To determine whether the protein complex binding the
⫺908 to ⫺893 contained STAT proteins, we performed
supershift analysis using antibodies directed against the
STAT proteins expressed in adipocytes. As shown in Fig.
5, the protein complex induced by PRL was fully supershifted with a STAT5A antibody (lane 5) and weakly
supershifted with an STAT5B antibody (lane 6). STAT1
and STAT3 antibodies had no effect on the mobility of the
complex (lanes 3 and 4). We also investigated the specificity of binding by STAT proteins by comparing the
binding induced by LIF (0.5 nmol/l), a cytokine that
activates STAT1 and STAT3 but not STAT5 in 3T3-L1
adipocytes (35). LIF stimulated binding to the ⫺908 to
⫺893 site by a protein complex that exhibited highly
reduced binding affinity and slightly faster mobility than
the complex induced by PRL (Fig. 5). Moreover, the
LIF-induced complex was supershifted by a STAT1 antibody (lane 8) but not with antibodies for STAT3 or
STAT5A (lanes 9 and 10). We used three other STAT3
antibodies capable of supershifting STAT3 complexes and
did not observe any STAT3 LIF-stimulated binding to the
⫺908 to ⫺893 site (data not shown).
Our data clearly demonstrate that the ⫺908 to ⫺893
region of the rat FAS promoter binds nuclear PRL-activated STAT5 proteins in vitro. To determine whether this
region of the FAS promoter contributed to the regulation
of FAS by PRL in living cells, we performed site-specific
mutagenesis to alter two basepairs at positions ⫺902 and
⫺901 within the rat FAS promoter (⫺1,594 to ⫹65)/
1972

FIG. 6. The ⴚ908 to ⴚ893 region of the rat FAS promoter confers
sensitivity to PRL. Proliferating 3T3-L1 cells were transiently transfected with the FAS (ⴚ1,594 to ⴙ65)/luciferase reporter wild-type
construct or with the FAS m901/902 (ⴚ1,594 to ⴙ65)/luciferase mutant
construct. Cells were also transfected with the TK/renilla construct to
normalize for transfection variability. After 48 h of transfection, cells
were stimulated with PRL (2.8 mol/l) for the times indicated. Relative
light units (RLU) were calculated by dividing firefly luciferase activity
by renilla luciferase activity. Results are shown as ⴞ SD. For each
experiment, three plates of cells were used for each particular condition. In addition, each experiment was performed on three independent batches of cells with similar results. Hence, each condition has
n ⴝ 9.

luciferase construct. We have shown that this mutation
abolished binding of PRL-induced proteins to this site (Fig.
4B and D). Transfection of the wild-type and mutant
constructs into 3T3-L1 cells revealed that the basal level of
luciferase activity was unaffected by mutation of the ⫺902
and ⫺901 bp of the FAS promoter (Fig. 6). However, the
60% decrease in luciferase activity induced by PRL for the
wild-type construct was eliminated with the mutation.
Thus, these data clearly indicate that the ⫺908 to ⫺893 site
of the FAS promoter is sensitive to PRL and suggest that
this site confers the negative regulation of FAS by PRLactivated STAT5A protein complexes.
DISCUSSION

The novel findings in this study include data demonstrating that FAS levels are decreased following stimulation
with activators of STAT5 in 3T3-L1 adipocytes, the identification of a PRL-responsive region of the rat FAS promoter, and the characterization of a STAT5 binding site in
this region. These results strongly suggest that STAT5A
directly represses the expression of FAS in adipocytes.
Moreover, our data indicate that STAT5A has an antilipogenic function in murine adipocytes, in addition to an
adipogenic role previously described by our laboratory (8)
and others (4,6,7).
Previous studies have shown that GH, an activator of
STAT5, attenuated the induction of FAS in adipocytes by
insulin in 3T3-F442A adipocytes (10) and decreased expression of FAS in vivo in pigs (11). We observed that two
activators of STAT5 in adipocytes, GH and PRL, decreased
protein and mRNA expression of FAS in 3T3-L1 adipocytes. These results are consistent with the findings that
GH in cows (36) and PRL in rats (24) can inhibit the
activity of FAS in adipose tissue. Surprisingly, our results
revealed that the effects of GH on FAS are transient and
reversible, whereas the effects of PRL are more pronounced with time. The differences in the action of these
two STAT5 activators may be due to receptor levels or
specific signal proteins that have yet to be identified.
Alternatively, the differences we observe in GH and PRL
effects on FAS in our murine cells may also be affected by
different species of hormones we used (sheep and pig) on
DIABETES, VOL. 54, JULY 2005
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murine cells. Our results show that PRL did not affect the
protein turnover of FAS but indicate that changes in FAS
levels are mediated at the transcriptional level. Our experiments are supported by other studies (25,28,37– 48) that
demonstrate that FAS can be modulated at the transcriptional level. However, increased turnover of FAS mRNA in
3T3-F442A adipocytes has been demonstrated as one of
the means through which GH attenuates the induction of
FAS by insulin (10). Nonetheless, our results strongly
suggest that the PRL-induced repression of FAS is mediated by an inhibition of transcription.
To elucidate the mechanism of transcriptional regulation by PRL, we investigated the regulation of the FAS
promoter. Although a previous study (28) indicated that
the ⫺112 to ⫹65 region of the rat FAS promoter was
sensitive to regulation by GH in murine cells, we did not
observe PRL-mediated regulation of the rat FAS promoter
within this region in murine cells (Fig. 3A). However, our
analysis of larger regions of the rat FAS promoter clearly
indicated that a PRL-responsive region existed between
⫺1,594 and ⫺700 of the rat FAS promoter (Fig. 3B). Yin,
Clarke, and Etherton (28) have previously shown that GH
attenuated the stimulation by insulin of the rat FAS
promoter (⫺112 to ⫹65)/luciferase construct, a region of
the promoter that does not contain a STAT consensus site.
Furthermore, in another study (37), it was demonstrated
that staurosporine, an inhibitor of JAK/STAT signaling, did
not block the effect of GH on insulin-stimulated FAS
expression in murine cells. Thus, it is unlikely that STAT5
proteins mediate the inhibitory effects of GH on insulin
regulation of FAS. Yet, in light of our current findings, we
postulate that the repression of basal levels of FAS by PRL
is directly regulated by STAT5 proteins via binding to a site
within the ⫺1,594 to ⫺700 region of the rat FAS promoter.
We also hypothesize that the delayed effects we observe
on FAS mRNA and protein are due to the stability of the
FAS mRNA and protein. Our studies indicate that FAS
protein is very stable (Fig. 2), and preliminary studies
suggest that the FAS mRNA is more stabile than other
adipocyte mRNAs (data not shown).
Since PRL is a potent activator of STAT5 (Fig. 1B), we
examined the rat FAS promoter for sites that resembled
the STAT consensus sequence, TTCNNNGAA. We identified four sites that were similar to the STAT consensus, but
our analysis by EMSA indicated that only one site, at
position ⫺908 to ⫺893, was bound by a PRL-induced
nuclear protein complex in a highly specific manner (Fig.
4). Similar results were obtained with GH (data not
shown). In our experiments, the PRL-induced protein
complex was fully supershifted by a STAT5A antibody
(Fig. 5). The functional significance of the ⫺908 to ⫺893
site was determined by mutating two nucleotides at positions ⫺902 and ⫺901, within the STAT5 binding site of the
rat FAS promoter (⫺1,594 to ⫹65)/luciferase construct.
Mutation of this site completely abrogated the downregulation by PRL that was observed with the wild-type construct (Fig. 6). Taken together, these data strongly suggest
that ⫺908 to ⫺893 of the rat FAS promoter is a STAT5
binding site, which confers the negative transcriptional
regulation of FAS by PRL. These results support our
hypothesis that STAT5 directly represses expression of
FAS in adipocytes.
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The association of increased transcription of FAS in
rodent obesity (49) and the inhibition of adipogenesis by
an allosteric inhibitor of FAS (26) are highly indicative that
regulation of FAS expression and activity in adipocytes is
an important control of energy homeostasis. The characterization of a STAT5 binding site in the rat FAS promoter
identifies a novel mechanism for repression of FAS expression. The ⫺908 to ⫺893 site of the rat FAS promoter is also
present in the murine FAS promoter (AL663090) at position ⫺895 to ⫺887. Interestingly, the human FAS promoter
(AF250144) contains a site at ⫺1,091 to ⫺1,083 (TTCGAG
GAA) that is different from the sequence identified from
the rodent promoters but complements the STAT consensus sequence TTCNNNGAA. Hence, although the precise
sequence of the STAT5 binding site is not conserved
across species, the binding by STAT5 to these sites in the
FAS promoter may be an evolutionarily retained mechanism of regulating FAS expression in adipose tissue.
Our observation that STAT5A, not other adipocyte
STATs, preferentially binds to the ⫺908 to ⫺893 site (Fig.
5) is consistent with previous studies (50,51) demonstrating that STAT proteins bind similar sequences but exhibit
subtle differences in affinity for nucleotides between and
beyond the half-sites of the palindrome. This specificity in
STAT binding may account for the distinct repertoire of
target genes regulated by each STAT protein (51). Our data
suggest that the regulation of transcription mediated by
the ⫺908 to ⫺893 region of the rat FAS promoter is
primarily regulated by STAT5A binding.
PRL has been shown to have antilipogenic effects in
adipose tissue through inhibition of LPL expression and
the repression of FAS (24) and LPL (18) activity. At this
time, our studies and others suggest that both PRL and GH
repress FAS expression. However, these growth factors
appear to have different effects (transient versus sustained) on FAS regulation. These differences may be
attributable to expression levels or actions of specific GH
and PRL signaling proteins and/or specific cell types.
Nonetheless, our results strongly suggest that PRL modulates the expression of FAS in adipocytes through STAT5A
and supports a role for STAT5 as a regulator of energy
balance in adipocytes. PRL appears to have dual functions,
positively and negatively affecting adipocyte gene expression. This hypothesis is supported by another study (13)
showing that STAT5 can act as a modulator of GH-induced
inhibition of aP2 expression. The association of STAT5
proteins with coactivators, corepressors, and other transcription factors likely affects the ability of STAT5A to
have adipogenic and antiadipogenic effects. Recent work
from our laboratory has demonstrated that the association
between STAT5A and the glucocorticoid receptor is highly
regulated during fat cell differentiation (8). Hence, cooperation between STAT5A and glucocorticoid receptor may
occur in the modulation of FAS, since glucocorticoids
have been demonstrated to affect FAS transcription and
activity in adipose tissue (52,53). We are currently investigating the cross talk between these pathways in adipocytes. In summary, we have observed that PRL represses
expression of FAS in adipocytes and negatively regulates
the rat FAS promoter. Our identification of a STAT5
binding site in the promoter of FAS characterizes a novel
mechanism of regulating FAS expression. In summary, we
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hypothesize that the regulation of FAS by STAT5 is likely
an important contribution to the maintenance of energy
homeostasis.
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